Antibody Drug Conjugates Market Landscape: Emerging Regions and Their Potential
The global antibody drug conjugates market size was estimated at USD 11.29 billion in 2023 and is projected to grow at a CAGR of 9.2% from 2024 to 2030. This can be attributed to the presence of a robust R&D pipeline. This, coupled with the growing incidence of cancer and increased demand for low-toxicity & effective drugs, is expected to drive market growth. Some of the key Antibody Drug Conjugates (ADCs) currently available in the market are Kadcyla (Genentech/Roche), Adcetris (Seattle Genetics), Enhertu (AstraZeneca/Daiichi Sankyo), Besponsa (Pfizer), Mylotarg (Pfizer), and Polivy (Genentech/Roche). ADCs are a novel category of drugs composed of an antibody linked-via a chemical linker-to a cytotoxic drug. Conventional chemotherapy is intended to eradicate fast-growing tumor cells. However, it can also damage healthy proliferating cells, which may produce undesirable effects. In contrast, ADC is designed to upsurge the efficacy of treatment and decrease systemic toxicity